Business Daily Media

LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in OS, PFS and ORR

  • Written by ACN Newswire - Press Releases

LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in OS, PFS and ORR

TOKYO, Dec 17, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the pivotal Phase 3 Study 309/KEYNOTE-775 trial evaluating the investigational use of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor

Read more //?#

3 Ways To Manage A Job Where There’s More Work Than You Can Handle

While having a job that you love is one of the greatest blessings in your life, having a job that you love but can’t seem to keep up with can caus...

Business Training

Power BI Examples Reports

In this article we will be looking at some Power BI Examples Reports. These reports are great for learning how to use Power BI effectively. In this...

Business Training

Basic Dropshipping Business Tips To Remember

During the pandemic one of the businesses which many people looked to get involved with was dropshipping, a great option if you know what you are do...

Business Training

6 International Expansion Strategies to Achieve Global Competitive Edge

Business growth has always been the number one priority of every business. Growing the business and expanding it from one city to a statewide lo...

Business Training

The Importance of Customer Feedback for Your Online Business

Your perception of your business is unique. It has helped you build up your brand and establish your presence online, and above all, it has beco...

Business Training

How COVID changed our shopping habits for good & what it means for the future

As Aussies say online shopping ‘came to the rescue’ in 2020 & 60% believe it will be even more important in 2021    COVID-19 has chang...

Business Training